Literature DB >> 7508478

Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA.

M L White1, J K Ma, C A Birr, P W Trown, S F Carroll.   

Abstract

A sensitive sandwich ELISA has been developed to measure levels of native bactericidal/permeability-increasing protein (BPI) as well as two recombinant forms of BPI (rBPI and rBPI23) in human body fluids. The linear range for the rBPI and rBPI23 standard curves were 100-6000 pg/ml and 25-800 pg/ml respectively. Recovery of different concentrations of rBPI spiked into pooled human plasma samples averaged 83% and ranged from 65% at 300 ng/ml to 97% at 3 ng/ml. Recovery of rBPI23 averaged 56% and ranged from 30% at 0.5 ng/ml to 90% at 50,000 ng/ml. Because LBP is present in normal human plasma and shares sequence homology with BPI, the effects of rLBP on the BPI ELISA were also evaluated. Under standard assay conditions, rLBP caused minimal interference with BPI detection. At 100 micrograms/ml, rLBP generated a signal equivalent to 3 ng/ml of rBPI and 0.6 ng/ml of rBPI23. Matched serum and plasma samples were collected from 20 healthy adults to measure endogenous levels of BPI. The range of BPI concentrations was < 0.2-2.1 ng/ml in plasma and 4.9-72.1 ng/ml in serum. Western blot analysis indicated that the BPI ELISA immunoreactivity in plasma and serum correlated with the presence of a protein doublet (M(r) approximately 60,000), which comigrated with native BPI extracted from human neutrophils. These data demonstrate that low levels of holo-BPI are present in plasma, and suggest that additional quantities of BPI were released from neutrophils during the process of coagulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508478     DOI: 10.1016/0022-1759(94)90091-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in rats.

Authors:  R J Bauer; K Der; N Ottah-Ihejeto; J Barrientos; A H Kung
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

2.  Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage.

Authors:  A N Kimmings; S J van Deventer; H Obertop; E A Rauws; K Huibregtse; D J Gouma
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

3.  Protective effect of bactericidal/permeability-increasing protein (rBPI21) in baboon sepsis is related to its antibacterial, not antiendotoxin, properties.

Authors:  G Schlag; H Redl; J Davies; P Scannon
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

4.  Immunoreactivity and bioactivity of lipopolysaccharide-binding protein in normal and heat-inactivated sera.

Authors:  K Mészáros; S Aberle; M White; J B Parent
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  Bactericidal/permeability-increasing protein is expressed by human dermal fibroblasts and upregulated by interleukin 4.

Authors:  Philipp H Reichel; Christine Seemann; Elena Csernok; Jens-M Schröder; Antje Müller; Wolfgang L Gross; Hendrik Schultz
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

6.  Human lipopolysaccharide-binding protein potentiates bactericidal activity of human bactericidal/permeability-increasing protein.

Authors:  A H Horwitz; R E Williams; G Nowakowski
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

7.  Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria.

Authors:  H Gazzano-Santoro; K Mészáros; C Birr; S F Carroll; G Theofan; A H Horwitz; E Lim; S Aberle; H Kasler; J B Parent
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

8.  Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein.

Authors:  J O Häggblom; A B Jokilammi-Siltanen; H Peuravuori; T J Nevalainen
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.